Certara Products Archives

Blog

Measuring metabolites in index clinical DDI studies

February 7, 2025A key drug development safety consideration is whether the drug candidate will interact…

CertaraFebruary 7, 2025

On-Demand Webinar

Machine Learning for Population PK Model Selection: Theory and Practice

Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…

CertaraFebruary 7, 2025

On-Demand Webinar

Standards for All: Controlling Your Metadata for Vendors, Study Sites, and Submission Datasets

Director of Product, Certara's Pinnacle 21Senior Principal CDISC Consultant, Certara's Pinnacle 21Achieve submission ready conformance…

CertaraFebruary 7, 2025

Blog

Best Practices for International Pharma Content Roll-Out

January 31, 2025 Pharmaceutical market access, sales, and field teams rely on high-quality, effective content…

CertaraJanuary 31, 2025

Blog

How to Validate Your Clinical Data Using FDA Validation Rules

January 30, 2025 For clinical data managers, understanding clinical data validation and applying FDA validation…

CertaraJanuary 30, 2025

Webinar

Phoenix Hosted: Cloud-Based PK/PD Software for Smarter, Faster Research

CertaraJanuary 30, 2025

On-Demand Webinar

Transforming Perspectives: 25 Years of PBPK Modeling in Drug-Drug Interactions

Vice President and Head of Global PK/PD and Pharmacometrics at Eli Lilly and Company Dr.…

CertaraJanuary 29, 2025

White Paper

The Benefits of Real-Time Nonclinical Safety Data Analysis

Learn how SEND Explorer software helps nonclinical drug developers streamline performing real-time toxicology assessments of…

CertaraJanuary 27, 2025

Blog

Achieve Clinical Data Transparency with the 4 Cs of Collaboration

In this blog, we look at how you can enhance clinical data transparency and make…

CertaraJanuary 15, 2025

Publication

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

CertaraJanuary 8, 2025

Certara Products

Measuring metabolites in index clinical DDI studies

Machine Learning for Population PK Model Selection: Theory and Practice

Standards for All: Controlling Your Metadata for Vendors, Study Sites, and Submission Datasets

Best Practices for International Pharma Content Roll-Out

How to Validate Your Clinical Data Using FDA Validation Rules

Phoenix Hosted: Cloud-Based PK/PD Software for Smarter, Faster Research

Transforming Perspectives: 25 Years of PBPK Modeling in Drug-Drug Interactions

The Benefits of Real-Time Nonclinical Safety Data Analysis

Achieve Clinical Data Transparency with the 4 Cs of Collaboration

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Newsletter sign up

Quick links

Solutions

Contact